EP0201187A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Determination of glycated (glycosylated) hemoglobin in blood
Assignee: Dako Denmark ApS
•
Filing: 1986-03-27
•
Granted: —
•
Expires: 2006-03-27
Abstract
Abstract The concentration of glycated hemoglobin, HbA lc , in hemoglobin from diabetic patients is regarded as a useful means of assessing the adequacy of diabetes control. This invention provides a monoclonal antibody which, due to its specific binding of HbA lc , can be used for the determination of HbA lc in blood samples by such analytical methods as radioimmuno assay or enzyme-linked immunosorbent assay.
Inventors
- 👤 Jesper Zeuthen
- 👤 Annette Prentö
- 👤 Viggo Kruse
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 01:10
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/72; G01N33/721; G01N33/723
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
23 words
A monoclonal antibody of rodent origin exhibiting a preferential binding to human HbA lc as compared with its binding to human HbA .
Claim 2
Dependent Claim
23 words
A monoclonal antibody of rodent origin exhibiting a preferential binding to human HbA lc as compared with its binding to human HbA .
Claim 3
Dependent Claim
32 words
A monoclonal antibody of rodent origin exhibiting a preferential binding to an epitope of HbA lc , which epitope comprises the glycated amino group of the N-terminal valine of the hemoglobin Aβ-chain.
Claim 4
Dependent Claim
32 words
A monoclonal antibody of rodent origin exhibiting a preferential binding to an epitope of HbA lc , which epitope comprises the glycated amino group of the N-terminal valine of the hemoglobin Aβ-chain.
Claim 5
Dependent Claim
21 words
A monoclonal antibody according to Claim 2, which is obtainable from the hybridoma cell line HEM 13F1 or a reclone thereof.
Claim 6
Dependent Claim
23 words
A monoclonal antibody according to Claim 3, wherein the reclone of the hybridoma cell line HEM 13F1 is the cell line HEM 13FlA4.
Claim 7
Dependent Claim
20 words
A monoclonal antibody according to Claim 2, which is obtainable from hybridoma cell line HEM 13F2 or a reclone thereof.
Claim 8
Dependent Claim
15 words
A monoclonal antibody according to anyone of Claims 2 to 5, in detectably labelled form.
Claim 9
Dependent Claim
10 words
A monoclonal antibody according to Claim 6, in biotinylated form.
Claim 10
Dependent Claim
55 words
A process for preparing a monoclonal antibody for use as a diagnostic aid for the determination of HbA lc , which process comprises cultivating in a growth medium a hybridoma cell line capable of producing a monoclonal antibody exhibiting a preferential binding to human HbA lc as compared with its binding to human HbA .
Claim 11
Dependent Claim
55 words
A process for preparing a monoclonal antibody for use as a diagnostic aid for the determination of HbA lc , which process comprises cultivating in a growth medium a hybridoma cell line capable of producing a monoclonal antibody exhibiting a preferential binding to human HbA lc as compared with its binding to human HbA .
Claim 12
Dependent Claim
56 words
A process for preparing a monoclonal antibody for use as a diagnostic aid for the determination of HbA lc , which process comprises cultivating in a growth medium a hybridoma cell line capable of producing a monoclonal antibody which binds preferentially an epitope comprising the glycated amino group of the N-terminal valine of the hemoglobin Aβ-chain.
Claim 13
Dependent Claim
56 words
A process for preparing a monoclonal antibody for use as a diagnostic aid for the determination of HbA lc , which process comprises cultivating in a growth medium a hybridoma cell line capable of producing a monoclonal antibody which binds preferentially an epitope comprising the glycated amino group of the N-terminal valine of the hemoglobin Aβ-chain.
Claim 14
Dependent Claim
21 words
A process according to Claim 9, wherein the hybridoma cell line is the cell line HEM 13F1 or a reclone thereof.
Claim 15
Dependent Claim
17 words
A process according to Claim 10, wherein the hybridoma cell line is hybridoma cell line HEM 13F1A4.
Claim 16
Dependent Claim
21 words
A process according to Claim 9, wherein the hybridoma cell line is the cell line HEM 13F2 or a reclone thereof.
Claim 17
Dependent Claim
17 words
A hybridoma cell line capable of producing a monoclonal antibody which binds preferentially to HbA lc .
Claim 18
Dependent Claim
17 words
A hybridoma cell line capable of producing a monoclonal antibody which binds preferentially to HbA lc .
Claim 19
Dependent Claim
20 words
A hybridoma cell line according to Claim 13, wherein the hybridoma cell line is HEM 13F1 or a reclone thereof.
Claim 20
Dependent Claim
16 words
A hybridoma cell line according to Claim 14, wherein the hybridoma cell line is HEM 13F1A4.
Claim 21
Dependent Claim
20 words
A hybridoma cell line according to Claim 13, wherein the hybridoma cell line is HEM 13F2 or a reclone thereof.
Claim 22
Dependent Claim
31 words
A method for the determination of HbA lc , which method comprises contacting hemoglobin A with a monoclonal antibody according to Claim 2 and measuring the amount of bound monoclonal antibody.
Claim 23
Dependent Claim
51 words
A kit for the determination of HbA lc , which kit comprises a carrier means being compartmentalized to receive in close confinement therein two or more containers, a first container containing the monoclonal antibody of Claim 2, and a second container comprising hemoglobin with a predetermined concentration of HbA lc .
Claim 24
Dependent Claim
45 words
A kit according to Claim 18, which further comprises a third container containing hemoglobin with a predetermined concentration of HbA lc , the predetermined concentration of HbA lc of the third container being different from the predetermined concentration of HbA lc of the second container.
Claim 25
Dependent Claim
23 words
A kit according to Claim 18 or 19, wherein the monoclonal antibody is in accordance with Claim 3, 4, 5, 6 or 7.
Claim 26
Dependent Claim
74 words
The applicant has informed the European Patent Office that, until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, the availability of the micro-organism(s) identified below, referred to in paragraph 3 of Rule 28 of the European Patent Convention, shall be effected only by the issue of a sample to an expert.
Claim 27
Dependent Claim
74 words
The applicant has informed the European Patent Office that, until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, the availability of the micro-organism(s) identified below, referred to in paragraph 3 of Rule 28 of the European Patent Convention, shall be effected only by the issue of a sample to an expert.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.